Biogen covers all bases for personalised approach to MS PharmaTimes Data is also being presented on Biogen's investigational MS drugs, such as Plegridy (pegylated interferon beta-1a), the pegylated version of its older blockbuster Avonex and daclizumab, a once-monthly subcutaneous injection being developed with AbbVie. |
